1. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Issue 1 (January 2021) Authors: Usmani, Saad Z; Hoering, Antje; Ailawadhi, Sikander; Sexton, Rachael; Lipe, Brea; Hita, Sandi Fredette; Valent, Jason; Rosenzweig, Michael; Zonder, Jeffrey A; Dhodapkar, Madhav; Callander, Natalie; Zimmerman, Todd; Voorhees, Peter M; Durie, Brian; Rajkumar, S Vincent; Richardson, Paul G; Orlowski... Journal: Lancet Issue: Volume 8:Issue 1(2021) Page Start: e45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. (28th February 2020) Authors: Chakraborty, Rajshekhar; Rybicki, Lisa; Nakashima, Megan O.; Dean, Robert M.; Faiman, Beth M.; Samaras, Christy J.; Rosko, Nathaniel; Dysert, Hayley; Valent, Jason; Anwer, Faiz Journal: British journal of haematology Issue: Volume 189:Number 6(2020) Page Start: 1074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Daratumumab proves safe and highly effective in AL amyloidosis. (25th June 2018) Authors: Khouri, Jack; Kin, Andrew; Thapa, Bicky; Reu, Frederic J.; Bumma, Naresh; Samaras, Christy J.; Liu, Hien D.; Karam, Mary A.; Reed, Janice; Mathur, Saveta; Faiman, Beth M.; Devries, Georgia; Zonder, Jeffrey; Valent, Jason Journal: British journal of haematology Issue: Volume 185:Number 2(2019) Page Start: 342 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience. (3rd July 2018) Authors: Ikram, Asad; Donnelly, Joseph P.; Sperry, Brett W.; Samaras, Christy; Valent, Jason; Hanna, Mazen Journal: Amyloid Issue: Volume 25:Number 3(2018) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients. (August 2022) Authors: Rafae, Abdul; Ehsan, Hamid; Wahab, Ahsan; Khan, Sana Irfan; Khan, Israr; Ashraf, Sara; Ali, Sundas; Khalid, Farhan; Neupane, Karun; Valent, Jason; Khouri, Jack; Samaras, Christy; Mazzoni, Sandra; Anwer, Faiz Journal: Critical reviews in oncology/hematology Issue: Volume 176(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. (5th January 2023) Authors: Dima, Danai; Li, Ang; Granat, Lauren M.; Dhillon, Puneet; Chamseddine, Fatima; Yalamanchali, Anirudh; Mirzai, Saeid; Wei, Wei; Samaras, Christy J.; Valent, Jason; Anwer, Faiz; Khouri, Jack Journal: British journal of haematology Issue: Volume 201:Number 2(2023) Page Start: 280 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Issue 3 (11th March 2020) Authors: Chari, Ajai; Cornell, Robert F.; Gasparetto, Cristina; Karanes, Chatchada; Matous, Jeffrey V.; Niesvizky, Ruben; Lunning, Matthew; Usmani, Saad Z.; Anderson, Larry D.; Chhabra, Saurabh; Girnius, Saulius; Shustik, Chaim; Stuart, Robert; Lee, Yihua; Salman, Zeena; Liu, Emily; Valent, Jason Journal: Hematological oncology Issue: Volume 38:Issue 3(2020) Page Start: 353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. Issue 6 (30th March 2022) Authors: Sanchorawala, Vaishali; Palladini, Giovanni; Minnema, Monique C.; Jaccard, Arnaud; Lee, Hans C.; Gibbs, Simon; Mollee, Peter; Venner, Christopher; Lu, Jin; Schönland, Stefan; Gatt, Moshe; Suzuki, Kenshi; Kim, Kihyun; Cibeira, María Teresa; Beksac, Meral; Libby, Edward; Valent, Jason; Hungria, Van... Journal: American journal of hematology Issue: Volume 97:Issue 6(2022) Page Start: 719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population. Issue 14 (6th December 2019) Authors: Chakraborty, Rajshekhar; Rybicki, Lisa; Tomer, Jacqulyn; Samaras, Christy J.; Faiman, Beth M.; Valent, Jason; Majhail, Navneet S. Journal: Leukemia & lymphoma Issue: Volume 60:Issue 14(2019) Page Start: 3544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Issue 11 (2nd November 2018) Authors: Chari, Ajai; Larson, Sarah; Holkova, Beata; Cornell, Robert F.; Gasparetto, Cristina; Karanes, Chatchada; Matous, Jeffrey V.; Niesvizky, Ruben; Valent, Jason; Lunning, Matthew; Usmani, Saad Z.; Anderson, Larry D.; Chang, Lipo; Lee, Yihua; Pak, Yvonne; Salman, Zeena; Graef, Thorsten; Bilotti, Eliz... Journal: Leukemia & lymphoma Issue: Volume 59:Issue 11(2018) Page Start: 2588 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗